Randomised, Parallel-Group, Multicentre, Multinational Phase 2 Study Comparing Edoxaban, an Oral Factor Xa Inhibitor, With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation

Thrombosis and Haemostasis - Germany
doi 10.1160/th10-01-0066
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Georg Thieme Verlag KG

Related search

Suboptimal Anticoagulant Management in Japanese Patients With Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention

Journal of Stroke and Cerebrovascular Diseases
SurgeryNeurologyCardiovascular MedicineRehabilitationCardiology
2017English

Cost-Effectiveness of Rivaroxaban for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation – A Multinational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Prevention of Cardiovascular Outcomes in Diabetic Patients With Atrial Fibrillation: Direct Oral Anticoagulants or Warfarin?

Clinical pharmacology and therapy
2019English

Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin

Circulation. Cardiovascular quality and outcomes
MedicineCardiovascular MedicineCardiology
2012English

Cost-Effectiveness Analysis of Apixaban Against Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation in Japan

Clinical Therapeutics
Pharmacology
2015English

Pcv75 - An Updated Cost-Effectiveness Pairwise Analysis of Apixaban and Warfarin for Stroke Prevention in Patients With Non- Valvular Atrial Fibrillation in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Transient Ischemic Attacks in Patients With Atrial Fibrillation: Implications for Secondary Prevention: The European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III Trial

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2004English

Pcv84 - Cost-Effectiveness Analysis of Apixaban Versus Edoxaban for Stroke Prevention in Non-Valvular Atrial Fibrillation Spanish Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of New Oral Anticoagulants Compared With Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy